NCT06736704 2026-03-13
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
15 trialsNCT05781048 2026-03-10
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
NCT07459998 2026-03-10
SKB103 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07460375 2026-03-10
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Not yet recruiting
NCT07172919 2026-03-06
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen
Phase 2 Recruiting
NCT05951608 2026-03-05
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Akeso
Phase 1/2 Active not recruiting
NCT06596473 2026-03-05
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07387068 2026-03-04
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Recruiting
NCT07446816 2026-03-03
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1 Recruiting
NCT06715124 2026-03-02
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Quanta Therapeutics
Phase 1 Active not recruiting
NCT07346846 2026-03-02
A Study of BGM-2121 in Patients With Advanced Solid Tumors
BioGate Precision Medicine Corp.
Phase 1 Not yet recruiting
NCT05083481 2026-02-27
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT05109975 2026-02-27
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Debiopharm International SA
Phase 1 Active not recruiting
NCT05914376 2026-02-27
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
Hangzhou Converd Co., Ltd.
Phase 1 Active not recruiting
NCT07413328 2026-02-27
HWS116 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1 Not yet recruiting